ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200

Also written as “SKB315 for injection” and “MK-1200”.

Its studies are led by 2 companies.

Drug pageAnti-Claudin 18.2 Antibody-drug Conjugate MK-1200: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since May 20, 20263 company-led studies, 2 open or runningNext primary completion: Jun 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Kelun Pharmaceuticalits history only22 open or runningphase 2since May 20, 2026Apr 21, 2022Jun 30, 2028phase 2 · NCT07609667
Merckits history only10 open or runningphase 2since Jan 26, 2024Jan 26, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 21, 2022First study: phase 1 study in Advanced Solid TumorsNew to Sichuan Kelun PharmaceuticalSichuan Kelun Pharmaceutical · NCT05367635 · 246 planned · China
  2. Jan 26, 2024Merck’s first study: phase 2 study in Advanced Solid TumorsNew to MerckMerck · NCT06242691 · 13 enrolled · United States, Australia, Chile and more
  3. May 20, 2026Phase 2 study in Gastroesophageal Junction AdenocarcinomaPhase 2 reachedSichuan Kelun Pharmaceutical · NCT07609667 · 80 planned · China

Ahead

  1. Jun 30, 2028Primary completion: phase 2 study in Gastroesophageal Junction AdenocarcinomaSichuan Kelun Pharmaceutical · NCT07609667

TargetBeta

CLDN18 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) that is site-specifically ”NCIt, by rule

Other programs on CLDN18

ProgramCompanyFurthest phaseStudies
zolbetuximabruleAstellas Pharmaphase 412
sonesitatug vedotinAstraZenecaphase 37
garetatug rezetecanJiangsu HengRui Medicinephase 37
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
tecotabart vedotinSino Biopharmaceuticalphase 36
arcotatug tavatecanruleInnovent Biologicsphase 35
terallethrinruleFutureGen Biopharmaceutical (Beijing)phase 33
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1biokin-shanghai-biopharmaceutical-co-ltdphase 33
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin 18.2 Antibody-drug Conjugate ASP546CruleAstellas Pharmaphase 22
givastomigrulei-mab-biopharma-us-limitedphase 22
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07609667Gastroesophageal Junction Adenocarcinoma · China2Not yet recruitingSichuan Kelun PharmaceuticalJun 30, 202880
NCT06242691Advanced Solid Tumors · United States, Australia, Chile and more2CompletedMerckJun 17, 202513
NCT05367635Advanced Solid Tumors · China1RecruitingSichuan Kelun PharmaceuticalJun 30, 2026246

How it is read

Names in the registry

  • “SKB315 for injection”, 2 entries
  • “MK-1200”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.